logo
Top Psychiatrists Recommend These ADHD Meds for Anxiety

Top Psychiatrists Recommend These ADHD Meds for Anxiety

When it comes to treating anxiety, especially in individuals who also have Attention Deficit Hyperactivity Disorder (ADHD), finding the right medication can be challenging. Many symptoms of anxiety and ADHD overlap, such as restlessness, trouble concentrating, and irritability. Fortunately, top psychiatrists have identified several best adhd medication for adults with anxiety that not only help with focus and hyperactivity but also offer significant relief from anxiety symptoms. Here's a closer look at the top ADHD medications often recommended by psychiatrists for managing anxiety.
When managing anxiety or depression, selecting the right medication can significantly influence treatment outcomes. Both medications work by affecting serotonin levels in the brain, yet they have distinct characteristics and side effect profiles. In the comparison of Zoloft vs lexapro, Zoloft may be more energizing and is often used for a broader range of conditions, including OCD and PTSD, while Lexapro is typically favored for its tolerability and fewer interactions. Consulting with a healthcare provider helps determine which option aligns best with individual needs, ensuring a personalized approach to mental health treatment.
Strattera is a non-stimulant medication approved by the FDA for the treatment of ADHD. Unlike traditional stimulants, Strattera works by selectively inhibiting the reuptake of norepinephrine, a neurotransmitter involved in attention and emotional regulation. Because it doesn't act on dopamine in the same way as stimulants, it carries a lower risk of dependency and is often favored for patients with co-occurring anxiety disorders.
Psychiatrists often recommend Strattera for individuals with generalized anxiety disorder (GAD) alongside ADHD because it provides cognitive benefits without worsening anxiety. Many patients find that Strattera helps improve focus while also easing symptoms such as worry, excessive fear, and physical tension.
Originally developed as a treatment for high blood pressure, Intuniv has been repurposed as a non-stimulant ADHD medication, especially effective in children and adolescents. It works by activating alpha-2A adrenergic receptors in the brain, which help regulate attention, impulsivity, and emotional responses.
What sets Intuniv apart is its calming effect. Psychiatrists often prescribe it for patients who experience high levels of emotional reactivity or stress. It can reduce anxiety symptoms like nervousness, sleep problems, and irritability, making it a popular choice for patients with both ADHD and anxiety.
Kapvay, an extended-release form of clonidine, is another non-stimulant option used to treat ADHD, especially in younger patients. Like Intuniv, Kapvay affects the alpha-2 adrenergic receptors, helping to improve attention while also reducing hyperactivity and impulsive behaviors.
Clonidine's sedative properties are particularly beneficial for patients with anxiety-related insomnia. Psychiatrists often recommend Kapvay for individuals who struggle with restlessness, racing thoughts, and trouble sleeping. Because it has a dual effect—calming the body and mind—it's frequently used in patients whose anxiety is physically overwhelming.
Though primarily an antidepressant, Wellbutrin is sometimes used off-label for ADHD treatment. It functions as a norepinephrine-dopamine reuptake inhibitor (NDRI), increasing the levels of both neurotransmitters in the brain. This dual action can enhance focus and reduce symptoms of depression and anxiety.
Wellbutrin is favored by psychiatrists for patients who have mild to moderate ADHD symptoms along with anxiety or depression. It doesn't carry the same side effect profile as stimulants and can be a good alternative for individuals who are sensitive to traditional ADHD medications or who have a history of substance use disorders.
Vyvanse is a stimulant that is commonly prescribed for moderate to severe ADHD. While stimulants are often thought to worsen anxiety, this is not always the case. Many patients report that treating their ADHD symptoms with Vyvanse leads to an overall reduction in anxiety because they can focus better and manage daily tasks more effectively.
Psychiatrists may recommend Vyvanse for patients whose anxiety is primarily a result of unmanaged ADHD. By improving executive function and reducing mental clutter, Vyvanse helps some individuals feel more in control, which indirectly reduces anxiety. However, it must be prescribed cautiously, as it can sometimes increase nervousness or insomnia in sensitive individuals.
Adderall XR is another stimulant that combines two amphetamine salts to target the dopamine and norepinephrine systems in the brain. Like Vyvanse, it's often prescribed for patients with ADHD and co-occurring anxiety—especially when anxiety is secondary to the distress caused by disorganization, forgetfulness, or impulsivity.
Top psychiatrists emphasize the importance of careful monitoring when using Adderall XR in patients with anxiety. While it can lead to significant improvements in focus and performance, it may also cause jitteriness or increased heart rate. For this reason, lower starting doses and close follow-ups are essential.
The decision to use a particular ADHD medication to manage anxiety depends on a variety of factors, including the severity of each condition, the patient's medical history, age, and potential for substance misuse. Non-stimulants are often preferred when anxiety is severe or pre-existing. Stimulants can be helpful when ADHD symptoms are driving the anxiety, but they require more careful titration and supervision.
It's also important to note that medication is just one piece of the puzzle. Psychiatrists often recommend combining pharmacological treatment with cognitive behavioral therapy (CBT), mindfulness practices, and lifestyle modifications for the best outcomes. Diet, sleep, and exercise all play crucial roles in regulating mood and attention.
Top psychiatrists understand that treating ADHD and anxiety together requires a balanced and thoughtful approach. While medications like Strattera, Intuniv, Kapvay, Wellbutrin, Vyvanse, and Adderall XR all offer potential benefits, the best choice depends on the individual's unique profile. A comprehensive evaluation by a licensed psychiatrist is essential for selecting the most effective and safest option. With the right treatment plan in place, many patients experience significant relief from both ADHD and anxiety symptoms—leading to better focus, improved emotional regulation, and a higher quality of life.
TIME BUSINESS NEWS
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)
Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)

Yahoo

time32 minutes ago

  • Yahoo

Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)

Alto Neuroscience, Inc. (NYSE:ANRO) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 26, Stifel reiterated its 'Buy' rating on Alto Neuroscience, Inc. (NYSE:ANRO) with a price target of $10. This decision came after the company announced Phase 2 proof-of-concept results for its drug ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. A close-up of a healthcare professional in a lab coat, handling a pipette with medications for neuroscience diseases. The trial showed mixed results. However, Stifel analysts noted that ALTO-203 showed significant positive effects in improving sustained attention and increased wakefulness. The strongest results were seen in patients with more abnormal theta/beta EEG ratios at baseline, which is a biomarker that can be used to help diagnose ADHD. Stifel described the trial as exploratory with low expectations, noting that although this program keeps some options open for Alto Neuroscience, Inc. (NYSE:ANRO), it does not change the core investment view as the company prioritizes its late-stage pipeline. The next steps for ALTO-203 are yet to be determined. Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on the development of treatment options for neuropsychiatric disorders. While we acknowledge the potential of ANRO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

Fed up with brands that use corn syrup and skim milk, this mother developed her own ‘clean' baby formula
Fed up with brands that use corn syrup and skim milk, this mother developed her own ‘clean' baby formula

TechCrunch

time33 minutes ago

  • TechCrunch

Fed up with brands that use corn syrup and skim milk, this mother developed her own ‘clean' baby formula

When Esther Hallam welcomed her daughter, Nara, into the world, she faced the challenge of searching for trustworthy brands that offered high-quality, organic infant formula in the U.S. Despite being available for nearly 160 years, the quality of infant formula options in the U.S. is still lacking, she believes. Many manufacturers opt for skim milk to cut costs, which allows them to add oils to meet nutritional requirements. Several formulas contain palm oil, soy, and corn syrup, which aren't recommended for infants due to their potential health risks. For instance, research has linked corn syrup to an increased risk of obesity, while palm oil has been shown to decrease calcium and fat absorption. 'I became fixated by the fact that there wasn't a good, organic infant formula that I trusted, that I wanted to feed my daughter in the United States, which is a first-world country,' Hallam told TechCrunch. For the past seven years, Hallam has been developing her own organic, whole-milk infant formula from scratch, with the help of scientists and pediatric nutritionists. Today marks the official launch of Nara Organics, which meets both European and U.S. safety standards, and is FDA-registered and USDA-certified. Most importantly, the formula is free from palm oil, soy, corn syrup, maltodextrin, and genetically modified organisms (GMOs), providing a clean option for conscientious parents looking to nourish their babies with the best possible ingredients. Nara Organics claims to have the highest percentage of milk fat of any formula sold in the U.S. It also has the lowest percentage of plant-based oils, as the use of whole milk means that less oil is needed to achieve the correct fat content. The ingredient list on the package includes an 'organic vegetable oil blend' made up of organic sunflower, coconut, and rapeseed oils, which provide essential fatty acids that support healthy development. Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW Image Credits:Nara Organics While there are several brands with organic formulas, such as Bobbie and ByHeart, these products are manufactured in the U.S. In contrast, Nara Organics chose not to produce its formula in American facilities, potentially due to previous issues with Cronobacter contamination, a germ that can survive in dry foods. In recent years, there have been several recalls of baby formula linked to outbreaks of Cronobacter. This is why the company prefers to manufacture its formula in Germany, which just so happens to be the birthplace of powdered infant formula. Chief marketing officer Meika Hollender explained to TechCrunch that the company's manufacturing partner utilizes technology 'that doesn't exist anywhere else in the world,' she said. 'A critical piece of infant formula, in terms of its shelf life, is how much oxygen gets into the can while you're sealing it. So if you go to facilities in the U.S., they're open. When you're filling, canning, and sealing the can, they're just sort of out in the open air of the facility. And at our facility, the cans actually go into this chamber that has no oxygen in them,' Hollender said. Nara has secured a total of $32 million from AlleyCorp, BBG Ventures, Corazon Ventures, Gingerbread Capital, and Torch Capital. Additionally, the company has attracted attention from high-profile celebrity investors, including tennis superstar Serena Williams, 'Jane the Virgin' actress Gina Rodriguez, and the creators of 'Nobody Wants This,' Erin and Sara Foster, among others. Nicky Hilton, fashion designer and philanthropist, is also an investor and advisor. 'I breastfed all of my three children, but they also all had formula,' Hilton told us. 'Every baby and parent is different, and not all mothers are able to breastfeed due to medical, physical, or personal reasons. I think there's so much judgment and unnecessary pressure about breastfeeding… It's really exciting to be a part of an innovative brand that is disrupting the baby formula market.' With this support, Nara Organics could position itself as a key player in the organic formula market, which was valued at approximately $20.7 billion in 2023 and is expected to reach $37 billion by 2032. Image Credits:Nara Organics The formula is now available for purchase on the company's website. Customers can choose the starter bundle for $36, which includes 2 cans. Alternatively, they can sign up for a subscription that delivers either 4 or 6 cans every 4 weeks, priced at $136 or $243, respectively. Each can makes about 25 4-ounce bottles. It can also be purchased through the company's free mobile app, which Hallam launched in 2018. The app is designed to assist users in tracking essential aspects of infant care, including monitoring baby feeding times, keeping a log of wet and soiled diapers, and tracking tummy time exercises. As part of its launch, the company is donating over 1,400 cans of infant formula to the Good+ Foundation, a nonprofit organization working to end multi-generational poverty by supplying essential items and services to under-resourced parents and caregivers.

The dangerously blurry line between wellness and medical tech
The dangerously blurry line between wellness and medical tech

The Verge

time34 minutes ago

  • The Verge

The dangerously blurry line between wellness and medical tech

Few things scratch my brain like a good beef. Kendrick vs. Drake. Justin Baldoni vs. Blake Lively. On my beat, it's usually two companies fighting over health tech patents. So-and-so copied a feature from so-and-so. The latest dispute on my radar is all about semantics. More specifically, the exact meaning of wellness. Let me catch you up. On July 15th, the Food and Drug Administration (FDA) sent Whoop a letter. In it, the FDA declared that Whoop — maker of a niche fitness tracker favored by elite athletes — had crossed a line. Its new Blood Pressure Insights feature, the regulator said, was being marketed to customers without undergoing the proper clearance process. In response, Whoop pulled out the W word: wellness. In the world of health and wearable tech, 'wellness' is sort of like a 'get out of jail free' card. Some advanced health features, like EKGs and atrial fibrillation notifications, require regulatory clearance before consumers can use them. These features could be interpreted as diagnostic in nature or prompt a person to make a medical decision. Others, like step tracking and blood oxygen measurements, don't require FDA oversight at all. They're simply meant to make living a healthy life easier by helping you visualize certain measurable markers. Those features fall under the wellness umbrella. They're 'just for fun.' Whoop's Blood Pressure Insights feature, however, lies in murkier territory. The way Whoop's feature works is that a user takes readings with a regular blood pressure cuff for calibration. Once that process is complete, Whoop says its tracker uses metrics like 'heart rate, heart rate variability, and blood flow patterns during sleep' to give an estimate of a person's systolic and diastolic blood pressure each morning. The FDA contends that 'providing blood pressure estimation is not a low-risk function' and that a blood pressure estimate inherently implies you're diagnosing hypo- or hypertension. In a statement, Whoop says it 'respectfully disagree[s]' and that this particular feature is more akin to tracking your sleeping respiratory rate. Under the wellness umbrella, Whoop argues it's able to bring an innovative feature to the masses more quickly. Whoop and the FDA both have points. It's not a stretch to think that a user may get a few 'high' blood pressure estimates, assume they have high blood pressure, and make health decisions informed by that assumption. At the same time, it's clearly labeled as a beta feature, and similar 'diagnostic adjacent' features are available without FDA regulation. I've lost count of how many sleep trackers claim to track 'breathing disturbances.' That may not be explicitly marketed as a sleep apnea detection metric (that would require FDA clearance), but that's semantics. The obvious reason to include it is to flag when a person might want to check themselves for sleep apnea. The crux of it all is identifying high- and low-risk features for causing harm. Many cases are clear-cut. Natural Cycles, for example, is a period tracking app that claims you can use it as digital contraception using temperature data from wearables like the Oura Ring. It's obvious that a regulatory body should vet a high-stakes feature like that. On the flip side, Samsung's new Antioxidant Index feature for its Galaxy Watch 8 is a silly metric that tells you whether you've eaten enough fruits and veggies. Even if it's inaccurate as hell (I was able to fool it by scanning a Cheez-It), it's not likely to harm your health. Where the FDA's current process falls short is the increasing number of features that lie somewhere in the middle. Take the Oura Ring. A friend just asked me whether they should get one based on a TikTok video. In said video, celebrity DJ Dillon Francis says the main reason he has an Oura Ring is because it predicts when he's getting sick. This is the Symptom Radar feature, which, in simple terms, flags when you might be getting sick — and it's based on real clinical research conducted during the COVID-19 pandemic. It sounds diagnostic, which requires FDA clearance. But it's not. It's considered a wellness feature because it doesn't tell you what you're falling ill with — just that you might be showing 'early signs of a health change.' And while there's a distinct difference between a diagnosis and a heads-up, it can feel awfully similar to a layperson. Also, Whoop isn't the only company exploring blood pressure tech. Samsung has a similar feature that's unavailable in the US, as it hasn't been cleared by the FDA. According to Bloomberg, Apple has also been working on an Apple Watch feature that flags when your blood pressure spikes above your baseline, but it reportedly won't spit out direct readings like a continuous glucose monitor would — possibly to avoid FDA clearance as a 'wellness' feature. Perhaps that means it's time we acknowledge that wellness isn't an innocuous word anymore. Beyond blood pressure, Samsung and Apple are also widely rumored to be working on blood glucose monitoring features, where the stakes for diabetics could be sky-high. If or when those features do become available, it's possible that companies will adjust how they work to more broadly fit under a wellness label. For instance, instead of glucose readings, you get a trend line or score. I'm skeptical of the average person being able to discern the nuance when even seasoned tech journalists sometimes struggle with the correct verbiage. Maybe it seems silly to sound the alarm over semantics. But as politicians advocate for greater wearable adoption, the stakes have never been higher. In a better, ideal world, companies would abolish phrases like 'clinically proven' or 'medical grade' from marketing. The FDA would figure out a clearer framework for the design of a wellness feature versus a medical one. But we don't live in an ideal world — and that means it's up to the consumer to know the difference. Frankly, that's not going so well. Perhaps that means it's time we acknowledge that wellness isn't an innocuous word anymore. Posts from this author will be added to your daily email digest and your homepage feed. See All by Victoria Song Posts from this topic will be added to your daily email digest and your homepage feed. See All Analysis Posts from this topic will be added to your daily email digest and your homepage feed. See All Features Posts from this topic will be added to your daily email digest and your homepage feed. See All Fitness Posts from this topic will be added to your daily email digest and your homepage feed. See All Gadgets Posts from this topic will be added to your daily email digest and your homepage feed. See All Health Posts from this topic will be added to your daily email digest and your homepage feed. See All Science Posts from this topic will be added to your daily email digest and your homepage feed. See All Wearable

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store